
Topic
Generic Entry
ANDA approvals, authorized generics, generic launch sequencing, patent expiry, and formulary shifts after generic entry.

Generics· June 13, 2026 · 17 min read
By Ran Chen#Orange Book#ANDA Approval#Generics

Generics· June 11, 2026 · 10 min read
Orange Book therapeutic equivalence: 48K products, 55% single-source, AB dominates
By Ran Chen#ANDA Approval#Orange Book#Generic Entry

Biosimilars· June 10, 2026 · 8 min read
Biosimilar competition decoded: 229 products across 20 reference drugs, one concentration
By Ran Chen#Biosimilars#Purple Book#Formulary Strategy

Policy· June 10, 2026 · 8 min read
The 2026–2032 patent cliff by the numbers: 11,000 patents, $200 billion at risk
By Ran Chen#Orange Book#Generic Entry#Biosimilars

Approvals· June 10, 2026 · 10 min read
The FDA approval engine: 29,135 applications, 78% generics, and a BLA surge
By Ran Chen#FDA Approval#Generic Entry#Biosimilars

Manufacturing· June 10, 2026 · 9 min read
Who supplies the world's essential medicines: 1,139 WHO-PQ products, 59% from India

Generics· June 9, 2026 · 9 min read
Dapagliflozin generic entry: Farxiga ANDA playbook and formulary impact
By Ran Chen#SGLT2 Inhibitor#ANDA Approval#Orange Book

Pricing & Access· May 31, 2026 · 9 min read
IRA MFP formulary inclusion exception: successor products and plan design

Pricing & Access· May 31, 2026 · 10 min read
MFP-selected drug generic and biosimilar entry monitoring for launch teams

Generics· May 27, 2026 · 12 min read
Hatch-Waxman 180-day exclusivity forfeiture guide
By Ran Chen#Generics#ANDA Approval#Orange Book